GlassScriptPhysician profile
Matthew Tomm
NPI 1336768050
$2,544.52
in general payments reported to CMS, 2019-2025
23 companies · $645 in 2025
The $645 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $588 · 2022: $391 · 2023: $504 · 2024: $417 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $274.16 | 2025 | |
| Medtronic, INC. | $244.82 | 2021 | |
| Axonics, INC. | $234.24 | 2021-2023 | Axonics, Bulkamid |
| Pfizer INC. | $224.00 | 2023-2024 | |
| Glaxosmithkline, LLC. | $220.76 | 2025 | Nucala |
| Dendreon Pharmaceuticals LLC | $200.51 | 2022-2023 | Provenge |
| Myovant Sciences INC. | $146.68 | 2021-2022 | |
| Procept Biorobotics Corporation | $137.49 | 2024 | Aquabeam System |
| Astrazeneca Pharmaceuticals LP | $131.32 | 2023-2024 | Lynparza |
| Janssen Biotech, INC. | $117.66 | 2022 | |
| Abbvie INC. | $117.06 | 2023-2025 | |
| Amgen INC. | $115.53 | 2022-2025 | Tezspire |
| Janssen Scientific Affairs, LLC | $81.93 | 2023 | Erleada |
| Boston Scientific Corporation | $75.55 | 2022-2023 | Spaceoar Vue System - 10ml |
| Sumitomo Pharma America, INC. | $48.44 | 2023-2025 | Gemtesa, Orgovyx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $47.62 | 2021-2025 | Xtandi |
| Phathom Pharmaceuticals, INC. | $25.39 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $24.13 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.96 | 2024 | Adstiladrin |
| Antares Pharma, INC. | $16.13 | 2022 | |
| Blue Earth Diagnostics | $16.11 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $13.46 | 2025 | Dupixent |
| Myriad Genetic Laboratories, INC. | $11.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Tomm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.